- Home
- DAWN
as 11-21-2024 4:00pm EST
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 1.6B | IPO Year: | 2021 |
| Target Price: | $36.17 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.30 - $18.07 | Next Earning Date: | 10-30-2024 |
| Revenue: | $101,953,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 44.21% |
Stock Insider Trading Activity of Day One Biopharmaceuticals Inc. (DAWN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Blackman Samuel C. | DAWN | HEAD OF R&D | Nov 15 '24 | Sell | $13.21 | 2,206 | $29,141.70 | 1,064,015 | |
| Dubow Adam | DAWN | GENERAL COUNSEL | Nov 15 '24 | Sell | $13.21 | 3,165 | $41,810.28 | 32,162 | |
| York Charles N II | DAWN | COO, CFO AND SECRETARY | Nov 15 '24 | Sell | $13.21 | 2,602 | $34,372.94 | 240,133 | |
| Blackman Samuel C. | DAWN | HEAD OF R&D | Nov 7 '24 | Sell | $16.03 | 11,245 | $180,286.59 | 1,064,015 | |
| Blackman Samuel C. | DAWN | HEAD OF R&D | Oct 31 '24 | Sell | $16.02 | 500 | $8,010.00 | 1,064,015 | |
| Blackman Samuel C. | DAWN | HEAD OF R&D | Sep 10 '24 | Sell | $14.22 | 30,000 | $426,675.00 | 1,064,015 |
Latest Day One Biopharmaceuticals Inc. News
DAWN Breaking Stock News: Dive into DAWN Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
GlobeNewswire
3 days ago
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
MT Newswires
9 days ago
Day One Biopharmaceuticals Insider Sold Shares Worth $456,223, According to a Recent SEC Filing
Zacks
15 days ago
Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?
Simply Wall St.
15 days ago
Exploring Three High Growth Tech Stocks in the United States
Simply Wall St.
18 days ago
Bullish: Analysts Just Made A Huge Upgrade To Their Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Forecasts
Simply Wall St.
20 days ago
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth
Zacks
22 days ago
Day One Biopharmaceuticals, Inc. (DAWN) Surpasses Q3 Earnings and Revenue Estimates
Compare DAWN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DAWN Day One Biopharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.